Simon Quick Advisors’s Neurogene NGNE Stock Holding History

Simon Quick Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,171	Closed	-$19.4K	–	355
2023 Q2	$19.4K	Hold	1,171	–	–	﹤0.01%	285
2023 Q1	$16.4K	Sell	1,171 -1,172	-50%	-$13.7K	﹤0.01%	276
2022 Q4	$23.9K	Hold	2,343	–	–	﹤0.01%	243
2022 Q3	$30K	Hold	2,343	–	–	﹤0.01%	199
2022 Q2	$49K	Buy	+2,343	New	+$57.1K	0.01%	175

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Simon Quick Advisors's NGNE Position: Q3 2023 in Review

Simon Quick Advisors sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 1,171 shares — an estimated $19.4K sold.

Simon Quick Advisors first reported a position in NGNE in Q2 2022 and held it in 5 quarters. The position peaked at $49K in Q2 2022. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

Simon Quick Advisors reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
Simon Quick Advisors sold 1,171 Neurogene shares in Q3 2023, an estimated $19.4K.
Simon Quick Advisors first reported a position in Neurogene in Q2 2022 and held it in 5 quarters.
Simon Quick Advisors's Neurogene position peaked at $49K in Q2 2022.
31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on Simon Quick Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.